{"id":51194,"date":"2025-12-17T22:47:21","date_gmt":"2025-12-17T14:47:21","guid":{"rendered":"https:\/\/flcube.com\/?p=51194"},"modified":"2025-12-17T22:47:22","modified_gmt":"2025-12-17T14:47:22","slug":"gsks-exdensur-wins-fda-approval-as-first-twice-yearly-asthma-biologic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51194","title":{"rendered":"GSK\u2019s Exdensur Wins FDA Approval as First Twice\u2011Yearly Asthma Biologic"},"content":{"rendered":"\n

GlaxoSmithKline plc<\/strong> (GSK, NYSE: GSK<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> approved Exdensur (depemokimab)<\/strong> as an add\u2011on maintenance treatment for severe asthma with eosinophilic phenotype<\/strong> in adult and pediatric patients aged 12 years and older<\/strong>. The drug is the first ultra\u2011long\u2011acting biologic<\/strong> enabling twice\u2011yearly dosing<\/strong> for respiratory diseases with type\u202f2 inflammation.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Approval Date<\/strong><\/td>17\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>U.S. FDA<\/td><\/tr>
Product<\/strong><\/td>Exdensur (depemokimab)<\/td><\/tr>
Indication<\/strong><\/td>Add\u2011on maintenance for severe eosinophilic asthma (age\u202f\u226512)<\/td><\/tr>
Dosing<\/strong><\/td>Twice yearly<\/strong> (every 26 weeks)<\/td><\/tr>
Innovation<\/strong><\/td>First ultra\u2011long\u2011acting biologic for type\u202f2 inflammatory respiratory diseases<\/td><\/tr>
Mechanism<\/strong><\/td>IL\u20115 inhibitor with extended half\u2011life<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 SWIFT-1 & SWIFT-2 Phase III Trials<\/h2>\n\n\n\n
Endpoint<\/th>Exdensur (depemokimab)<\/th>Placebo (SOC)<\/th>Reduction<\/th><\/tr><\/thead>
SWIFT\u20111 Annualized Exacerbations<\/strong><\/td>58% reduction<\/strong><\/td>Standard of care<\/td>p\u202f<\u202f0.001<\/td><\/tr>
SWIFT\u20112 Annualized Exacerbations<\/strong><\/td>48% reduction<\/strong><\/td>Standard of care<\/td>p\u202f<\u202f0.001<\/td><\/tr>
Treatment Duration<\/strong><\/td>Two doses per year (52 weeks)<\/td>\u2014<\/td>Sustained efficacy<\/td><\/tr>
Safety Profile<\/strong><\/td>Well\u2011tolerated<\/td>Similar rate\/severity of side effects<\/td>Comparable to placebo<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity & Competitive Landscape<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Implication<\/th><\/tr><\/thead>
Severe Asthma Prevalence<\/strong><\/td>25\u201130 million<\/strong> patients globally<\/td>~50% have eosinophilic phenotype<\/td><\/tr>
Biologic Market<\/strong><\/td>$18\u201122 billion<\/strong> (2025)<\/td>Dominated by anti\u2011IL\u20115\/IL\u20115R agents (Nucala, Fasenra, Dupixent)<\/td><\/tr>
Twice\u2011Yearly Advantage<\/strong><\/td>Reduces treatment burden vs. monthly\/quarterly competitors<\/td>First ultra\u2011long\u2011acting agent<\/strong> with Q6M dosing<\/td><\/tr>
Peak Sales Potential<\/strong><\/td>$3\u20115 billion<\/strong> (global estimate)<\/td>Captures 15\u201120% of severe eosinophilic asthma segment<\/td><\/tr>
Pricing Strategy<\/strong><\/td>Premium pricing justified by dosing convenience<\/td>Potential for favorable payer negotiations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n